CELL INTELLIGENCE · 肿瘤细胞治疗研究

肿瘤免疫微环境与局部晚期直肠癌术前放化疗反应：来自 STAR-01 研究队列的结果

Tumor Immune Microenvironment and Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer: Results From the STAR-01 Study Cohort.

在 LARC 中，CRT 重塑免疫细胞内容的类型和数量，对某些免疫群体的影响与肿瘤消退和临床结果相关。

lisocabtagene maraleucel 在 3L+ FL 中持久疗效和可控的长期安全性：TRANSCEND FL 的 3 年更新

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

评估完全缓解/缓解率作为复发/难治性慢性淋巴细胞白血病的替代终点

Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.

Epcoritamab 联合 GemOx 治疗不适合移植的复发/难治性 DLBCL：EPCORE NHL-2 试验结果

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

Odronextamab 单药治疗 CAR-T 细胞治疗后进展的 R/R DLBCL：ELM-1 研究的主要分析

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

纳武利尤单抗和利妥昔单抗用于初治滤泡性淋巴瘤：2 期 1st FLOR 研究

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

华氏巨球蛋白血症——最新综述：第 2 部分——聚焦治疗

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.

WM 无法治愈，但治疗可以提高生存率。WM/LPL 患者应在出现症状时开始治疗，IgM 水平不应决定 WM 治疗。当前指南建议采用各种初始个性化治疗，通常是化学免疫疗法 (CIT) 或 BTK 抑制剂 (BTKi)。

弥漫大 B 细胞淋巴瘤免疫治疗的未来

The future of immunotherapy for diffuse large B-cell lymphoma.

靶向广泛 B 细胞恶性肿瘤患者的异体 CD20xCD22 双靶点 CAR 的临床前证据

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies.

COVID-19 与肿瘤：接受免疫治疗和免疫抑制性抗肿瘤治疗患者的特殊考量

COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies.